Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 51 results
Filters: First Letter Of Last Name is M  [Clear All Filters]
Found 51 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

M

Ma Q, Forrest A, Rosenkranz SL, et al. "Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers." Biopharm Drug Dispos. 2008;29(2):91-101.
Macatangay BJC, Zheng L, Rinaldo CR, et al. "Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181." Clin. Vaccine Immunol.. 2010;17(9):1452-9.
Manion M, Rodriguez B, Medvik K, et al. "Interferon-alpha administration enhances CD8+ T cell activation in HIV infection." PLoS ONE. 2012;7(1):e30306.
Marc LG, Testa MA, Walker AM, et al. "Educational attainment and response to HAART during initial therapy for HIV-1 infection." J Psychosom Res. 2007;63(2):207-16.
Margolis DM, A Mukherjee L, Fletcher CV, et al. "The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection." AIDS. 2007;21(15):2025-32.
Markowitz M, Vaida F, C Hare B, et al. "The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection." J. Infect. Dis.. 2010;201(9):1298-302.
Marks KM, Kitch D, Chung RT, et al. "Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239." J. Acquir. Immune Defic. Syndr.. 2014;65(3):345-9.
Marra CM, Zhao Y, Clifford DB, et al. "Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance." AIDS. 2009;23(11):1359-66.
Mathad JS, Gupte N, Balagopal A, et al. "Sex-related Differences in Inflammatory and Immune Activation Markers before and after combined Antiretroviral Therapy Initiation." J. Acquir. Immune Defic. Syndr.. 2016.
Matoga MM, Hosseinipour MC, Aga E, et al. "Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings." Antivir. Ther. (Lond.). 2016.
Mave V, Erlandson KM, Gupte N, et al. "Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults." J. Infect. Dis.. 2016;214(1):65-72.
May S, Degruttola V. "Nonparametric tests for two-group comparisons of dependent observations obtained at varying time points." Biometrics. 2007;63(1):194-200.
McCausland MR, Juchnowski SM, Zidar DA, et al. "Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy." PLoS ONE. 2015;10(10):e0139474.
McComsey GA, Kendall MA, Tebas P, et al. "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV." AIDS. 2007;21(18):2473-82.
McComsey GA, Moser C, Currier J, et al. "Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s." Clin. Infect. Dis.. 2016;62(7):853-62.
McComsey GA, Kang M, Ross AC, et al. "Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy." HIV Clin Trials. 2008;9(2):126-36.
McComsey GA, Kitch D, Daar ES, et al. "Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir." AIDS. 2012;26(11):1371-85.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
McComsey GA, Walker UA, Budhathoki CB, et al. "Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229." AIDS. 2010;24(16):2507-15.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
McComsey GA, Kitch D, Sax PE, et al. "Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s." Clin. Infect. Dis.. 2011;53(2):185-96.
McComsey GA, Kitch D, Sax PE, et al. "Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202." J. Acquir. Immune Defic. Syndr.. 2014;65(2):167-74.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
McKinnon JE, Mailliard RB, Swindells S, et al. "Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201)." PLoS ONE. 2014;9(5):e95524.
McLaren PJ, Ripke S, Pelak K, et al. "Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans." Hum. Mol. Genet.. 2012;21(19):4334-47.
McLaren PJ, Coulonges C, Ripke S, et al. "Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls." PLoS Pathog.. 2013;9(7):e1003515.
McLaughlin BE, Baumgarth N, Bigos M, et al. "Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach." Cytometry A. 2008;73(5):400-10.
McLaughlin BE, Baumgarth N, Bigos M, et al. "Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part II: Panel performance across different instrument platforms." Cytometry A. 2008;73(5):411-20.
McLinden RJ, Paris RM, Polonis VR, et al. "Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)." AIDS. 2012;26(1):1-9.
McMahon DK, Zheng L, Hitti J, et al. "Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV." Clin. Infect. Dis.. 2013;56(7):1044-51.

Pages